PDX Model

MSK-LX40-R

Sex: Male

Histology: Small cell lung cancer

Key Mutations: TP53 H179R, RB1 S567*, NOTCH1 P2Rfs*31,

MYCL Amplified

Molecular Characteristics: MSK-IMPACT, whole exome sequencing

Matched Normal: Yes

Treatment: LDE225 + cisplatin + etoposide, extensive cisplatin and

etoposide treatment in PDX

Site: Lung

Paired: Yes

Comments: Chemoresistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes.

MSK Office of Technology Development Contact: Alexandra Buga, MS, MBA, Licensing Associate, T: 646-888-1078, e-mail: bugaa@mskcc.org.

Stage of Development

Ready to use

Indications